Cargando…
Intelligent Telehealth in Pharmacovigilance: A Future Perspective
Pharmacovigilance improves patient safety by detecting and preventing adverse drug events. However, challenges exist that limit adverse drug event detection, resulting in many adverse drug events being underreported or inaccurately reported. One challenge includes having access to large data sets fr...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9112241/ https://www.ncbi.nlm.nih.gov/pubmed/35579810 http://dx.doi.org/10.1007/s40264-022-01172-5 |
_version_ | 1784709378966814720 |
---|---|
author | Edrees, Heba Song, Wenyu Syrowatka, Ania Simona, Aurélien Amato, Mary G. Bates, David W. |
author_facet | Edrees, Heba Song, Wenyu Syrowatka, Ania Simona, Aurélien Amato, Mary G. Bates, David W. |
author_sort | Edrees, Heba |
collection | PubMed |
description | Pharmacovigilance improves patient safety by detecting and preventing adverse drug events. However, challenges exist that limit adverse drug event detection, resulting in many adverse drug events being underreported or inaccurately reported. One challenge includes having access to large data sets from various sources including electronic health records and wearable medical devices. Artificial intelligence, including machine learning methods, such as natural language processing and deep learning, can detect and extract information about adverse drug events, thus automating the pharmacovigilance process and improving the surveillance of known and documented adverse drug events. In addition, with the increased demand for telehealth services, for managing both acute and chronic diseases, artificial intelligence methods can play a role in detecting and preventing adverse drug events. In this review, we discuss two use cases of how artificial intelligence methods may be useful to improve the quality of pharmacovigilance and the role of artificial intelligence in telehealth practices. |
format | Online Article Text |
id | pubmed-9112241 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-91122412022-05-17 Intelligent Telehealth in Pharmacovigilance: A Future Perspective Edrees, Heba Song, Wenyu Syrowatka, Ania Simona, Aurélien Amato, Mary G. Bates, David W. Drug Saf Leading Article Pharmacovigilance improves patient safety by detecting and preventing adverse drug events. However, challenges exist that limit adverse drug event detection, resulting in many adverse drug events being underreported or inaccurately reported. One challenge includes having access to large data sets from various sources including electronic health records and wearable medical devices. Artificial intelligence, including machine learning methods, such as natural language processing and deep learning, can detect and extract information about adverse drug events, thus automating the pharmacovigilance process and improving the surveillance of known and documented adverse drug events. In addition, with the increased demand for telehealth services, for managing both acute and chronic diseases, artificial intelligence methods can play a role in detecting and preventing adverse drug events. In this review, we discuss two use cases of how artificial intelligence methods may be useful to improve the quality of pharmacovigilance and the role of artificial intelligence in telehealth practices. Springer International Publishing 2022-05-17 2022 /pmc/articles/PMC9112241/ /pubmed/35579810 http://dx.doi.org/10.1007/s40264-022-01172-5 Text en © The Author(s), under exclusive licence to Springer Nature Switzerland AG 2022 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Leading Article Edrees, Heba Song, Wenyu Syrowatka, Ania Simona, Aurélien Amato, Mary G. Bates, David W. Intelligent Telehealth in Pharmacovigilance: A Future Perspective |
title | Intelligent Telehealth in Pharmacovigilance: A Future Perspective |
title_full | Intelligent Telehealth in Pharmacovigilance: A Future Perspective |
title_fullStr | Intelligent Telehealth in Pharmacovigilance: A Future Perspective |
title_full_unstemmed | Intelligent Telehealth in Pharmacovigilance: A Future Perspective |
title_short | Intelligent Telehealth in Pharmacovigilance: A Future Perspective |
title_sort | intelligent telehealth in pharmacovigilance: a future perspective |
topic | Leading Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9112241/ https://www.ncbi.nlm.nih.gov/pubmed/35579810 http://dx.doi.org/10.1007/s40264-022-01172-5 |
work_keys_str_mv | AT edreesheba intelligenttelehealthinpharmacovigilanceafutureperspective AT songwenyu intelligenttelehealthinpharmacovigilanceafutureperspective AT syrowatkaania intelligenttelehealthinpharmacovigilanceafutureperspective AT simonaaurelien intelligenttelehealthinpharmacovigilanceafutureperspective AT amatomaryg intelligenttelehealthinpharmacovigilanceafutureperspective AT batesdavidw intelligenttelehealthinpharmacovigilanceafutureperspective |